

Reshma Kewalramani MD, FASN
One Amgen Center Drive
Thousand Oaks, CA 91320
(805) 447-6742
reshmak@amgen.com

Employment History:

Amgen Experience

Vice President, June 2014-Present
Head, US Medical Organization
Global Medical Organization
Amgen

Vice President, November 2010- June 2014
Global Clinical Development,
Nephrology and Metabolic Therapeutic Area Head
Amgen

Executive Director, January 2008-November 2010
Global Clinical Development,
Renal Anemia Program Area
Amgen

Executive Director March 2007-December 2007
Global Clinical Development,
Bone Therapeutic Area
Amgen

Medical Affairs, August 2004-March 2007
Nephrology Therapeutic Area
Amgen

Prior Experience

Intern Internal Medicine Massachusetts General Hospital

Resident Internal Medicine Massachusetts General Hospital

Fellow Nephrology Brigham & Women's Hospital
Massachusetts General Hospital
Boston Children's Hospital

Clinical & Research Harvard Medical School
Instructor

Physician Massachusetts Institute of
Technology Medical Department

Physician Massachusetts Eye and Ear Institute
Medical Department

Boards, Committees:

Board of Directors	Kidney Health Initiative
Steering Committee	Clinical Trials Transformation Initiative (CTTI)
Fellow	American Society of Nephrology

Education:

1998	B.A. (Honors)	Boston University
1998	M.D. (Honors)	Boston University School of Medicine
2003	Program in Clinical Effectiveness	Harvard School of Public Health

Licensure and Certification:

2000	State of MA, Board of Registration in Medicine
2002	Board Certified, Internal Medicine
2003	Board Certified, Nephrology
2009	State of CA, Medical Board of Registration

Select Honors & Awards:

1993	Phi Beta Kappa, Boston University
1998	Alpha Omega Alpha
1998	American College of Physicians Award
1998	Massachusetts Medical Society's Fifth Annual Scholars Award
1998	American Medical Women's Association Janet M. Glasgow Memorial Achievement Citation
1998	Henry J. Bakst Award in Community Medicine
1999	Dr. John Dittmer and Dr. Linda Wright Award for Excellence in Teaching Rebecca Lee Award for Achievement by Women in Medicine
2002	Massachusetts General Hospital Department of Medicine Excellence in Teaching Award
2004	Harvard Medical School Teaching Award
2010	Amgen GCO Award
2010	Fellow, American Society of Nephrology

Select Publications:

[Overcoming Barriers in Kidney Health-Forging a Platform for Innovation.](#)

Linde PG, Archdeacon P, Breyer MD, Ibrahim T, Inrig JK, **Kewalramani R**, Lee CC, Neuland CY, Roy-Chaudhury P, Sloand JA, Meyer R, Smith KA, Snook J, West M, Falk RJ.

J Am Soc Nephrol. 2016 Apr 28. pii: ASN.2015090976. [Epub ahead of print]

PMID: 27127187

[Similar articles](#)

Select item 27108247

[Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy \(TREAT\).](#)

Sabe MA, Claggett B, Burdmann EA, Desai AS, Ivanovich P, **Kewalramani R**, Lewis EF, McMurray JJ, Olson KA, Parfrey P, Solomon SD, Pfeffer MA.

J Am Heart Assoc. 2016 Apr 23;5(4). pii: e002850. doi: 10.1161/JAHA.115.002850.

PMID: 27108247 **Free Article**

[Similar articles](#)

Select item 26684933

[Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor.](#)

Bushinsky DA, Block GA, Martin KJ, Bell G, Huang S, Sun Y, Spiegel DM, Walsh L, Mix TC, **Kewalramani R**.

Am J Nephrol. 2015;42(5):379-88. doi: 10.1159/000442754. Epub 2015 Dec 19.

PMID: 26684933

[Similar articles](#)

Select item 26434934

[AMG 151 \(ARRY-403\), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.](#)

Katz L, Manamley N, Snyder WJ, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, **Kewalramani R**, Pellacani A.

Diabetes Obes Metab. 2016 Feb;18(2):191-5. doi: 10.1111/dom.12586. Epub 2015 Dec 14.

PMID: 26434934

[Similar articles](#)

Select item 26299230

[Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.](#)

Lewis EF, Claggett B, Parfrey PS, Burdmann EA, McMurray JJ, Solomon SD, Levey AS, Ivanovich P, Eckardt KU, **Kewalramani R**, Toto R, Pfeffer MA.

Am Heart J. 2015 Aug;170(2):322-9. doi: 10.1016/j.ahj.2015.05.008. Epub 2015 May 22.

PMID: 26299230

Albuminuria and racial disparities in the risk for ESRD. McClellan WM, Warnock DG, Judd S, Muntner P, Kewalramani R, Cushman M, McClure LA, Newsome BB, Howard G. J Am Soc Nephrol. 2011 Sep;22(9):1721-8.

Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, Solomon SD, Pfeffer MA. *Am J Kidney Dis.* 2011 Aug 4.

Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD. *Nephrol Dial Transplant.* 2011 May;26(5):1583-91. Epub 2010 Sep 22.

Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Warnock DG, Muntner P, McCullough PA, Zhang X, McClure LA, Zakai N, Cushman M, Newsome BB, Kewalramani R, Steffes MW, Howard G, McClellan WM, REGARDS Investigators. *American Journal of Kidney Diseases.* 56(5):861-71, 2010 Nov.

Prevalence and severity of chronic kidney disease and anemia in the nursing home population. McClellan WM, Resnick B, Lei L, Bradbury BD, Sciarra A, Kewalramani R, Ouslander JG. *Journal of the American Medical Directors Association.* 11(1):33-41, 2010 Jan.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators. *New England Journal of Medicine.* 361(21):2019-32, 2009 Nov 19.

Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. *Drugs & Aging.* 26(8):665-75, 2009. Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Sciarra A, Kewalramani R.

Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H, TREAT Investigators. *American Journal of Kidney Diseases.* 54(1):59-69, 2009 Jul.

Chronic kidney disease and US healthcare resource utilization in a nationally representative sample. Alexander M. Bradbury BD. Kewalramani R. Barlev A. Mohanty SA. Globe D. *American Journal of Nephrology*. 29(5):473-82, 2009.

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents. *Current Medical Research & Opinion*. 25(1):123-31, 2009 Jan. Silver MR. Geronemus R. Krause M. Chen CY. Kewalramani R. Stehman-Breen C

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Goldhahn J. Scheele WH. Mitlak BH. Abadie E. Aspenberg P. Augat P. Brandi ML. Burlet N. Chines A. Delmas PD. Dupin-Roger I. Ethgen D. Hanson B. Hartl F. Kanis JA. Kewalramani R. Laslop A. Marsh D. Ormarsdottir S. Rizzoli R. Santora A. Schmidmaier G. Wagener M. Reginster JY. *Bone*. 43(2):343-7, 2008 Aug

Association of anemia correction with health related quality of life in patients not on dialysis. Alexander M. Kewalramani R. Agodoa I. Globe D. *Current Medical Research & Opinion*. 23(12):2997-3008, 2007 Dec.

Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families. Globe D. Glidden D. Hertel J. Thomas J. Ackerman M. Chidolue F. Blanco B. Borden A. Goss TF. Xu X. Kewalramani R. *Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association*. 34(2):151-61, 2007 Mar-Apr.

Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. Krause MW. Raja R. Agarwal A. Silver MR. Scarlata D. Sciarra A. Kewalramani R. *Drugs & Aging*. 26(8):665-75, 2009.

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents. Silver MR. Geronemus R. Krause M. Chen CY. Kewalramani R. Stehman-Breen C. *Current Medical Research & Opinion*. 25(1):123-31, 2009 Jan.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA. Burdmann EA. Chen CY. Cooper ME. de Zeeuw D. Eckardt KU. Feyzi JM. Ivanovich P. Kewalramani R. Levey AS. Lewis EF. McGill JB. McMurray JJ. Parfrey P. Parving HH. Remuzzi G. Singh AK. Solomon SD. Toto R. TREAT Investigators. *New England Journal of Medicine*. 361(21):2019-32, 2009 Nov 19.

Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. Bernardo M. Crawford P. Hertel J. Sholer C. Xu X. Goss T. Kewalramani R. Globe D. *Journal of Managed Care Pharmacy*. 12(9):714-25, 2006 Nov-Dec.

CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. Yamada A. Salama AD. Sho M. Najafian N. Ito T. Forman JP. Kewalramani R. Sandner S. Harada H. Clarkson MR. Mandelbrot DA. Sharpe AH. Oshima H. Yagita H. Chalasani G. Lakkis FG. Auchincloss H Jr. Sayegh MH. *Journal of Immunology*. 174(3):1357-64, 2005 Feb 1.

Pharmacoepidemiology of anemia in kidney transplant recipients. Winkelmayr WC. Kewalramani R. Rutstein M. Gabardi S. Vonvisger T. Chandraker A. *Journal of the American Society of Nephrology*. 15(5):1347-52, 2004 May. .

Calcium signaling induced by adhesion mediates protein tyrosine phosphorylation and is independent of pHi. Trinkaus-Randall V. Kewalramani R. Payne J. Cornell-Bell A. *Journal of Cellular Physiology*. 184(3):385-99, 2000 Sep.

Expression of integrin receptors on plasma membranes of primary corneal epithelial cells is matrix specific. Grushkin-Lerner LS. Kewalramani R. Trinkaus-Randall V. *Experimental Eye Research*. 64(3):323-34, 1997 Mar.